Aktuellt
SENASTE
Redeye provides its initial take on MedCap’s Q4 2024 report, which came in broadly below our initial estimates and in line with the company’s profit warning in mid-January. We judge that positives from the report include a continued solid financial position that leaves plenty of room for further M&A, and the company announced a bolt-on deal in connection with its report. Notable negatives include underperformance across all segments, though we judge some one-off factors led to numbers looking worse than what we can expect in coming quarters.
LÄS MER
